Telo is developing therapeutics for a wide range of tumors based on their discovery of the mechanism that drives the oncogenic function of TERT promoter mutations. The novel mechanism holds the promise that inhibition of cell proliferation can be targeted only to active cancer cells. Telo’s first indication will be TERT promotor mutant glioblastoma which represents ~83% of all glioblastoma tumors.
